Prior to joining Volastra, Lyuben worked in oncology drug discovery at Schrodinger across multiple assets, including leading the biology for the CDC7 kinase inhibitor pre-clinical program. Prior to Schrodinger, Lyuben worked in the Oncology R&D at GSK, where he focused on drug discovery in the ubiquitin dependent degradation pathways and translational research in immuno-oncology.

He started his career in the biotech industry at Rigel Pharm. in South San Francisco, CA were he was leading drug discovery efforts in the field of ubiquitin ligase inhibitors.

Lyuben completed his postdoctoral training at the Yale University School of Medicine in the departments of Genetics and Pathology, where his research interests were focused on the cell cycle regulation and the DNA damage checkpoint pathways.

He received an M.S. in cell biology from the Sofia Univ. and Ph.D. in molecular biology and biochemistry from the Institute of Molecular Biology in Sofia, Bulgaria.